Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, Borchiellini D, Bensalah K, Schlürmann F, Ladoire S, Parier B, Bernhard JC, Cassuto O, Albigès L, Thibault C, Ingels A, Cherifi F, Waeckel T, Flippot R, Geoffrois L, Walz J, Gravis G, Barthélémy P. Pignot G, et al. Among authors: roubaud g. World J Urol. 2025 Jan 2;43(1):54. doi: 10.1007/s00345-024-05361-y. World J Urol. 2025. PMID: 39747746
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response.
Guégan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, Cousin S, Roubaud G, Cabart M, Leroy L, Lebreton C, Rey C, Lara O, Odin O, Brunet M, Vanhersecke L, Gruyters EO, Achour I, Belcaid L, Le Moulec S, Grellety T, Bessede A, Italiano A. Guégan JP, et al. Among authors: roubaud g. Cell Rep Med. 2024 Dec 17;5(12):101831. doi: 10.1016/j.xcrm.2024.101831. Epub 2024 Nov 25. Cell Rep Med. 2024. PMID: 39591972 Free article.
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease.
Ploussard G, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G, Olivier J, Dariane C, Mathieu R, Rozet F, Peyrottes A, Roubaud G, Renard-Penna R, Sargos P, Supiot S, Turpin L, Rouprêt M; Comité de Cancérologie de l’Association Française d’Urologie, Groupe Prostate, Maison de l’Urologie. Ploussard G, et al. Among authors: roubaud g. Fr J Urol. 2024 Nov;34(12):102717. doi: 10.1016/j.fjurol.2024.102717. Fr J Urol. 2024. PMID: 39581668 Review.
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance.
Ploussard G, Dariane C, Mathieu R, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G, Olivier J, Rozet F, Peyrottes A, Renard-Penna R, Sargos P, Supiot S, Turpin L, Roubaud G, Rouprêt M; Comité de Cancérologie de l’Association Française d’Urologie, Groupe Prostate, Maison de l’Urologie. Ploussard G, et al. Among authors: roubaud g. Fr J Urol. 2024 Nov;34(12):102710. doi: 10.1016/j.fjurol.2024.102710. Fr J Urol. 2024. PMID: 39581665 Review.
Anatomic Factors Associated with Complications After Radical Prostatectomy: A Systematic Review and Meta-analysis.
Peyrottes A, Dariane C, Baboudjian M, Barret E, Brureau L, Fiard G, Fromont G, Mathieu R, Olivier J, Renard-Penna R, Roubaud G, Rouprêt M, Sargos P, Supiot S, de la Taille A, Turpin L, Desgrandchamps F, Ploussard G, Masson-Lecomte A; French Oncology Committee from the Association Française d’Urologie. Peyrottes A, et al. Among authors: roubaud g. Eur Urol Oncol. 2024 Nov 18:S2588-9311(24)00247-5. doi: 10.1016/j.euo.2024.10.018. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39562217 Review.
Radiation therapy for stage IIA/IIB seminomas: Back to the future?
Le Guévelou J, Nicosia L, Blanchard P, Ralite F, Durand X, Marchesi V, Roubaud G, Sargos P. Le Guévelou J, et al. Among authors: roubaud g. Radiother Oncol. 2025 Jan;202:110626. doi: 10.1016/j.radonc.2024.110626. Epub 2024 Nov 16. Radiother Oncol. 2025. PMID: 39557127
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR. Rathkopf DE, et al. Among authors: roubaud g. Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.09.003. Online ahead of print. Eur Urol. 2024. PMID: 39317633 Free article.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. Morris MJ, et al. Among authors: roubaud g. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Clinical Trial.
116 results